Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Oxford BioMedica plc    OXB   GB0006648157

OXFORD BIOMEDICA PLC (OXB)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time CHI-X EUROPE LIMITED. - 04/23 11:38:50 am
11.9700 GBp   -0.42%
03/12OXFORD BIOMEDIC : annual earnings release
02/16OXFORD BIOMEDIC : inks $100m gene therapy deal
AQ
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
11.42(c) 11.3(c) 11.82(c) 12.02(c) 12.049 Last
4 713 657 8 728 893 6 528 125 5 150 510 3 562 681 Volume
-1.04% -1.05% +4.60% +1.69% +0.24% Change
More quotes
Financials (GBP)
Sales 2018 49,8 M
EBIT 2018 -1,36 M
Net income 2018 -3,08 M
Debt 2018 15,4 M
Yield 2018 -
Sales 2019 62,0 M
EBIT 2019 1,79 M
Net income 2019 -0,04 M
Debt 2019 31,8 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 111,81
EV / Sales2018 8,23x
EV / Sales2019 6,87x
Capitalization 395 M
More Financials
Company
Oxford Biomedica Ltd. operates as a biopharmaceutical company, which focus on biotechnology research and development, and the related manufacturing.It operates through the Partnering and R&D segments.The Partnering segment provides lentiviral vector bioprocessing and process development services to... 
More about the company
Surperformance© ratings of Oxford BioMedica plc
Trading Rating : Investor Rating :
More Ratings
Latest news on OXFORD BIOMEDICA PLC
03/12OXFORD BIOMEDICA PLC : annual earnings release
02/16OXFORD BIOMEDICA : signs collaboration agreement with Bioverativ
AQ
02/16OXFORD BIOMEDICA : inks $100m gene therapy deal
AQ
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/15OXFORD BIOMEDICA : Announces Collaboration and Licence Agreement with Bioverativ..
PU
01/29OXFORD BIOMEDICA : US investors swooping in on British biotechs
AQ
01/23OXFORD BIOMEDICA : announces £3 million grant awarded by Innovate UK
PU
01/17OXFORD BIOMEDICA : notes the US FDA Priority Review for Kymriah™ for adult..
PU
2017OXFORD BIOMEDICA : notes the primary analysis results from the pivotal JULIET tr..
PU
2017OXFORD BIOMEDICA : notes the CTL019 MAA submission to the EMA for children, youn..
PU
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/09$OXB Biomedica 2 directors bought/maiden bought: Two Directors at Oxford Bio.. 
03/24Oxford Biomedica downgraded by Zacks Investment Research to hold.  
03/23Annual Forecast for Oxford Biomedica (2018) #stocks #trading ...  
03/23Annual Forecast for Oxford Biomedica (2018) #stocks #trading ...  
03/21$OXBDF - Oxford Biomedica to Post FY2022 Earnings of $0.01 Per Share, Jefferi.. 
More tweets
Qtime:83
News from SeekingAlpha
03/16Oxford Biomedica PLC 2017 Q4 - Results - Earnings Call Slides 
2017Oxford Biomedica PLC reports 1H results 
2017The CTL019 Adcom Mists Begin To Clear 
2017Oxford BioMedica (OXBDF) Presents At Jefferies 2017 Global Healthcare Confere.. 
2017SNIPPET ROUNDUP : Novartis' Allogeneic CAR-T Drive And Astra's IL-4 Interest 
Chart OXFORD BIOMEDICA PLC
Duration : Period :
Oxford BioMedica plc Technical Analysis Chart | OXB | GB0006648157 | 4-Traders
Technical analysis trends OXFORD BIOMEDICA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 0,16  GBP
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
John Dawson Chief Executive Officer & Executive Director
Lorenzo M. Tallarigo Non-Executive Chairman
Stuart Paynter Chief Financial Officer & Director
Kyriacos Mitrophanous Chief Scientific Officer
James Miskin Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD BIOMEDICA PLC35.82%552
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998